<DOC>
	<DOCNO>NCT02462122</DOCNO>
	<brief_summary>Safety Efficacy IDP-118 treatment plaque psoriasis</brief_summary>
	<brief_title>Safety Efficacy IDP-118 Treatment Plaque Psoriasis</brief_title>
	<detailed_description>A Phase 3 , Multicenter , Double-Blind , Randomized , Vehicle Controlled Clinical Study Assess Safety Efficacy IDP-118 Treatment Plaque Psoriasis</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Key Male female , race , least 18 year age ( inclusive ) . Freely provide verbal write informed consent . Has area plaque psoriasis appropriate topical treatment cover BSA least 3 % , 12 % . The face , scalp , palm , sol , axillae intertriginous area exclude calculation . Is willing able avoid prolong exposure treatment area ultraviolet radiation ( natural artificial ) duration study . Has clinical diagnosis psoriasis Baseline visit IGA score 3 4 . ( The face , scalp , palm , sol , axillae intertriginous area exclude assessment ) . Key Has spontaneously improve rapidly deteriorate plaque psoriasis pustular psoriasis , determine investigator . Presents psoriasis treat prescription medication fail respond treatment , even partially temporarily , determine investigator . Presents concurrent skin condition could interfere evaluation treatment area , determine investigator . Is pregnant , nursing infant , plan pregnancy study period . Has receive treatment investigational drug device within 60 day 5 drug half life ( whichever longer ) prior Baseline visit , concurrently participate another clinical study investigational drug device .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>